These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 35978148)
21. The Stabilizing Excipients in Dry State Therapeutic Phage Formulations. Zhang Y; Zhang H; Ghosh D AAPS PharmSciTech; 2020 May; 21(4):133. PubMed ID: 32415395 [TBL] [Abstract][Full Text] [Related]
22. What is the value of faster acting prandial insulin? Focus on ultra rapid lispro. Heise T; Piras de Oliveira C; Juneja R; Ribeiro A; Chigutsa F; Blevins T Diabetes Obes Metab; 2022 Sep; 24(9):1689-1701. PubMed ID: 35593434 [TBL] [Abstract][Full Text] [Related]
23. Engineering Insulin Cold Chain Resilience to Improve Global Access. Maikawa CL; Mann JL; Kannan A; Meis CM; Grosskopf AK; Ou BS; Autzen AAA; Fuller GG; Maahs DM; Appel EA Biomacromolecules; 2021 Aug; 22(8):3386-3395. PubMed ID: 34213889 [TBL] [Abstract][Full Text] [Related]
24. Poly(trehalose methacrylate) as an Excipient for Insulin Stabilization: Mechanism and Safety. Gelb MB; Messina KMM; Vinciguerra D; Ko JH; Collins J; Tamboline M; Xu S; Ibarrondo FJ; Maynard HD ACS Appl Mater Interfaces; 2022 Aug; 14(33):37410-37423. PubMed ID: 35968684 [TBL] [Abstract][Full Text] [Related]
25. Antimicrobial Excipient-Induced Reversible Association of Therapeutic Peptides in Parenteral Formulations. D'Addio SM; Su Y; Yin D; Zhang J; Kemp E; Gindy ME J Pharm Sci; 2021 Feb; 110(2):850-859. PubMed ID: 32980392 [TBL] [Abstract][Full Text] [Related]
26. Peptide Optimization at the Drug Discovery-Development Interface: Tailoring of Physicochemical Properties Toward Specific Formulation Requirements. Evers A; Pfeiffer-Marek S; Bossart M; Heubel C; Stock U; Tiwari G; Gebauer B; Elshorst B; Pfenninger A; Lukasczyk U; Hessler G; Kamm W; Wagner M J Pharm Sci; 2019 Apr; 108(4):1404-1414. PubMed ID: 30528197 [TBL] [Abstract][Full Text] [Related]
27. Hydroxylpropyl-β-cyclodextrin as Potential Excipient to Prevent Stress-Induced Aggregation in Liquid Protein Formulations. Stolzke T; Krieg F; Peng T; Zhang H; Häusler O; Brandenbusch C Molecules; 2022 Aug; 27(16):. PubMed ID: 36014329 [TBL] [Abstract][Full Text] [Related]
28. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities. Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340 [TBL] [Abstract][Full Text] [Related]
29. Near Infrared Spectroscopy as a PAT tool for monitoring and control of protein and excipient concentration in ultrafiltration of highly concentrated antibody formulations. Thakur G; Hebbi V; Rathore AS Int J Pharm; 2021 May; 600():120456. PubMed ID: 33711473 [TBL] [Abstract][Full Text] [Related]
30. Towards an improved understanding of drug excipient interactions to enable rapid optimization of nanosuspension formulations. Ferrar JA; Sellers BD; Chan C; Leung DH Int J Pharm; 2020 Mar; 578():119094. PubMed ID: 32006625 [TBL] [Abstract][Full Text] [Related]
31. Simplified choice of suitable excipients within biologics formulation design using protein-protein interaction- and water activity-maps. Stolzke T; Brandenbusch C Eur J Pharm Biopharm; 2022 Jul; 176():153-167. PubMed ID: 35643368 [TBL] [Abstract][Full Text] [Related]
33. Role of ultrafast-acting insulin analogues in the management of diabetes. Kruger DF; Novak LM J Am Assoc Nurse Pract; 2019 Sep; 31(9):537-548. PubMed ID: 31385938 [TBL] [Abstract][Full Text] [Related]
34. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Kamerzell TJ; Esfandiary R; Joshi SB; Middaugh CR; Volkin DB Adv Drug Deliv Rev; 2011 Oct; 63(13):1118-59. PubMed ID: 21855584 [TBL] [Abstract][Full Text] [Related]
35. Zinc oxide as a new antimicrobial preservative of topical products: interactions with common formulation ingredients. Pasquet J; Chevalier Y; Couval E; Bouvier D; Bolzinger MA Int J Pharm; 2015 Feb; 479(1):88-95. PubMed ID: 25527211 [TBL] [Abstract][Full Text] [Related]
36. Excipient selection can significantly affect solid-state phase transformation in formulation during wet granulation. Airaksinen S; Karjalainen M; Kivikero N; Westermarck S; Shevchenko A; Rantanen J; Yliruusi J AAPS PharmSciTech; 2005 Oct; 6(2):E311-22. PubMed ID: 16353990 [TBL] [Abstract][Full Text] [Related]
38. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System. Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647 [TBL] [Abstract][Full Text] [Related]
39. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering. Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466 [TBL] [Abstract][Full Text] [Related]